Review: Long-acting β2-agonists and inhaled corticosteroids reduce exacerbations in chronic obstructive pulmonary disease

May 2004
ACP Journal Club;May/Jun2004, Vol. 140 Issue 3, p58
Academic Journal
This article focuses on the effects of commonly used treatments for chronic obstructive pulmonary disease on patient outcomes. In patients with chronic obstructive pulmonary disease, long-acting (LA) β[sub 2]-agonists and inhaled corticosteroids, with and without LA β[sub 2]As, reduce exacerbations, but not mortality. Analysis was restricted to randomized controlled trials, with blinded drug interventions where placebo was possible. Ascertainment of outcomes, complete or near-complete follow-up data, and well-balanced baseline characteristics in treatment and control groups.


Related Articles

  • Review: inhaled corticosteroids do not reduce mortality but increase pneumonia in COPD. Rees, P. John // Evidence Based Medicine;Jun2009, Vol. 14 Issue 3, p8 

    The article offers information on the advantages and disadvantages of inhaled corticosteroid (ICS) therapy in treating patients with stable chronic obstructive pulmonary disease (COPD). It notes that inhaled cortecosteroids with placebo or inhaled medications can contribute to mortality,...

  • Alterações espirométricas em doenças obstrutivas: afinal, o quanto é relevante? Soares, André Luis Pinto; de Castro Pereira, Carlos Alberto; Rodrigues, Silvia Carla // Jornal Brasileiro de Pneumologia;ene/feb2013, Vol. 39 Issue 1, p56 

    Objective: To establish the upper limits for changes in FEV1, slow vital capacity (SVC), FVC, and inspiratory capacity (IC) after placebo administration in patients with airflow obstruction. Methods: One hundred and two adults with airflow obstruction (FEV1 = 62 ± 19% of predicted) were...

  • Which Inhaler Combination is Best for COPD Treatment? Elliott, William T. // Clinical Oncology Alert;Apr2007 Pharmacology Watch, p1 

    The article discusses two studies which have looked at the effects of various inhaler combinations on outcomes in patients with chronic obstructive pulmonary disease (COPD). According to a study that was published in the February 22, 2007 issue of "New England Journal of Medicine," the mortality...

  • The "Towards a Revolution in COPD Health" study. D'Urzo, Anthony D. // Canadian Family Physician;May2008, Vol. 54, p740 

    The article considers whether salmeterol and fluticasone propionate combination reduces all-cause mortality compared with placebo in patients with chronic obstructive pulmonary disease. According to the author, treatment with salmeterol and fluticasone propionate combination does not...

  • Adherence to inhaled therapy, mortality and hospital admission in COPD. J Vestbo // Thorax;Nov2009, Vol. 64 Issue 11, p939 

    BACKGROUND: Little is known about adherence to inhaled medication in chronic obstructive pulmonary disease (COPD) and the impact on mortality and morbidity. METHODS: Data on drug adherence from a randomised double-blind trial comparing inhaled salmeterol 50 µg + fluticasone propionate 500...

  • Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Mcgarvey, Lorcan P.; John, Matthias; Anderson, Julie A.; Zvarich, Michael; Wise, Robert A. // Thorax;May2007, Vol. 62 Issue 5, p411 

    Background: TORCH (Towards a Revolution in COPD Health) is an international multicentre, randomised, placebo-controlled clinical trial of inhaled fluticasone propionate/salmeterol combination treatment and its monotherapy components for maintenance treatment of moderately to severely impaired...

  • Acidosis, non-invasive ventilation and mortality in hospitalised COPD exacerbations. C M Roberts // Thorax;Jan2011, Vol. 66 Issue 1, p43 

    BACKGROUND: Reports of non-invasive ventilation (NIV) use in clinical practice reveal higher mortality rates than in corresponding randomised clinical trials. AIM: To explore factors related to chronic obstructive pulmonary disease (COPD) admissions and NIV use that may explain some of the...

  • Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Sin, D. D.; Wu, L.; Anderson, J. A.; Anthonisen, N. R.; Buist, A. S.; Burge, P. S.; Calverley, P. M.; Connett, J. E.; Lindmark, B.; Pauwels, R. A.; Postma, D. S.; Soriano, J. B.; Szafranski, W.; Vestbo, J. // Thorax;Dec2005, Vol. 60 Issue 12, p992 

    Background: Clinical studies suggest that inhaled corticosteroids reduce exacerbations and improve health status in chronic obstructive pulmonary disease (COPD). However, their effect on mortality is unknown. Methods: A pooled analysis, based on intention to treat, of individual patient data...

  • Efficacy of once-daily indacaterol 75 μg relative to alternative bronchodilators in COPD: A study level and a patient level network meta-analysis. Cope, Shannon; Jie Zhang; Williams, James; Jansen, Jeroen P. // BMC Pulmonary Medicine;2012, Vol. 12 Issue 1, p29 

    Background: The objective of this study was to evaluate the comparative efficacy of indacaterol 75 µg once daily (OD), tiotropium 18 µg OD, salmeterol 50 µg twice daily (BID), formoterol 12 µg BID, and placebo for the treatment of chronic obstructive pulmonary disease (COPD) based on...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics